Price
CHART BY
Frequently asked questions
What is Novavax's market capitalization?
The market capitalization of Novavax is $1.10B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Novavax's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Novavax is 2.56. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Novavax?
Novavax's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $2.651. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Novavax's stock?
Currently, 7 analysts cover Novavax's stock, with a consensus target price of $13.43. Analyst ratings provide insights into the stock's expected performance.
What is Novavax's revenue over the trailing twelve months?
Over the trailing twelve months, Novavax reported a revenue of $1.25B.
What is the EBITDA for Novavax?
Novavax's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $467.50M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Novavax?
Novavax has a free cash flow of -$196.61M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Novavax have, and what sector and industry does it belong to?
Novavax employs approximately 952 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Novavax's shares?
The free float of Novavax is 147.54M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.10B
- EPS (TTM)
- $2.651
- Free Float
- 147.54M
- P/E ratio (TTM)
- 2.56
- Revenue (TTM)
- $1.25B
- EBITDA (TTM)
- $467.50M
- Free Cashflow (TTM)
- -$196.61M
Pricing
- 1D span
- $6.581$6.832
- 52W span
- $5.015$17.81
Analyst Ratings
The price target is $13.43 and the stock is covered by 7 analysts.
Buy
3
Hold
2
Sell
2
Information
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
- Employees
- 952
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US6700024010
- Primary Ticker
- NVAX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet